How much cash does Regenxbio generate?

Regenxbio (RGNX) generated -$233.8M in operating cash flow over the trailing twelve months.

What is Regenxbio's free cash flow?

After $2.6M of capital expenditures, Regenxbio's free cash flow was -$236.4M over the trailing twelve months, down 171.9% year over year.

Where does Regenxbio's cash flow data come from?

Every line is extracted from Regenxbio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Regenxbio RGNX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$290.01M-49.6%	-$193.88M-9.0%	-$177.92M-1.3%	-$175.57M-11.3%	-$157.69M+30.6%
Depreciation and amortization	$15.52M-0.6%	$15.62M-1.0%	$15.77M-0.5%	$15.84M-0.9%	$15.99M-1.4%
Stock-based compensation	$34.64M+0.2%	$34.56M-3.3%	$35.73M-2.4%	$36.62M-2.1%	$37.4M-2.8%
Change in accounts receivable	-$9.02M-218%	$7.66M+842%	-$1.03M—	——	——
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	-$2.02M-980%	$229K+102%	-$10.49M—	——	——
Change in other assets	$2.53M+312%	$613K+1,058%	-$64K—	——	——
Change in other liabilities	-$58K+98.1%	-$3M—	——	——	——
Other working capital changes	-$626K-4.9%	-$597K+58.7%	-$1.44M—	——	——
Change in deferred revenue	——	——	——	——	——
Change in prepaid expenses	——	——	——	——	——
Change in other current assets	-$1.58M-141%	-$658K+82.4%	-$3.73M—	——	——
Net cash from operating activities	-$233.78M-88.6%	-$123.96M-20.0%	-$103.3M-17.5%	-$87.89M-4.6%	-$84.04M+51.5%
Capital expenditures	$2.63M+8.7%	$2.41M-19.1%	$2.99M+5.9%	$2.82M-2.9%	$2.9M+19.2%
Net cash from investing activities	——	——	——	-$5.16M-104%	$135.27M+30.4%
Proceeds from issuance of common stock	$314K-1.3%	$318K+19.5%	$266K-59.9%	$664K-14.7%	$778K-48.5%
Net cash from financing activities	——	——	——	——	——
Net increase (decrease) in cash	——	——	——	——	——
Income taxes paid	——	$285K+45.6%	$195.75K+83.8%	$106.5K+517%	$17.25K+124%
Accretion (Amortization) of Discounts and Premiums, Investments	$5.29M-3.5%	$5.48M+2.1%	$5.37M+10.4%	$4.86M+2.4%	$4.75M+14.6%
Accounts payable	——	——	——	——	——
Accrued expenses and other liabilities	-$2.02M-980%	$229K+102%	-$10.49M—	——	——
Deferred revenue	——	——	——	——	——
Increase Decrease In Operating Lease Liabilities	-$8.93M-3.5%	-$8.63M-12.3%	-$7.68M+9.2%	-$8.46M-2.4%	-$8.26M-2.2%
Increase Decrease In Operating Lease Right Of Use Assets	-$6.72M-1.0%	-$6.65M-0.8%	-$6.6M-1.7%	-$6.49M-2.9%	-$6.31M-1.8%
Increase (Decrease) in Other Current Assets	-$1.58M-141%	-$658K+82.4%	-$3.73M—	——	——
Increase (Decrease) in Prepaid Expense	——	——	——	——	——
Non Cash Interest Expense	$16.93M+31.2%	$12.9M-4.3%	$13.48M+56.5%	$8.62M+67.8%	$5.14M-15.8%
Other Noncash Income (Expense)	-$626K-4.9%	-$597K+58.7%	-$1.44M—	——	——
Issuance of stock under employee stock plans	——	——	——	——	——
Repayments Under Royalty Monetization Liabilities Net Of Interest	$35.88M+27.7%	$28.1M+7.8%	$26.06M-13.7%	$30.2M—	——
Taxes Paid Related To Net Settlement Of Stock Based Awards	——	——	——	——	——
Accrued payables for capital expenditures	——	——	——	——	$432.25K+27.5%
Deferred Equity Offering Costs In Accounts Payable And Accrued Expenses And Other Current Liabilities	——	——	——	——	$309.5K+39.4%
Deferred Equity Offering Costs Reclassified	——	$499K-6.1%	$531.25K-5.7%	$563.5K-5.4%	$595.75K-5.1%
Cash Paid For Interest Under Royalty Monetization Liabilities	——	$32.11M+24.8%	$25.72M+33.0%	$19.33M+49.3%	$12.95M+97.4%
Income Taxes Paid, Net	——	$285K+45.6%	$195.75K+83.8%	$106.5K+517%	$17.25K+124%
Free cash flow	-$236.4M-87.1%	-$126.38M-18.9%	-$106.28M-17.2%	-$90.71M-4.3%	-$86.94M+50.5%
Free cash flow	-$236.4M-87.1%	-$126.38M-18.9%	-$106.28M-17.2%	-$90.71M-4.3%	-$86.94M+50.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Regenxbio.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Regenxbio generate?: Regenxbio (RGNX) generated -$233.8M in operating cash flow over the trailing twelve months.
What is Regenxbio's free cash flow?: After $2.6M of capital expenditures, Regenxbio's free cash flow was -$236.4M over the trailing twelve months, down 171.9% year over year.
Where does Regenxbio's cash flow data come from?: Every line is extracted from Regenxbio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.